Lifetime: New approach to fighting influenza Advertise on CTVNews.ca
About
Vasomune Therapeutics is a private biotechnology company developing AV-001, a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by AV-001 plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.
.